×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
NASDAQ:CRXT

Clarus Therapeutics (CRXT) Stock Forecast, Price & News

$0.38
+0.01 (+2.70%)
(As of 05/26/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.33
$0.41
50-Day Range
$0.37
$2.31
52-Week Range
$0.33
$31.24
Volume
5.37 million shs
Average Volume
8.42 million shs
Market Capitalization
$9.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.81
30 days | 90 days | 365 days | Advanced Chart
Receive CRXT News and Ratings via Email

Sign-up to receive the latest news and ratings for Clarus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Clarus Therapeutics logo

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Headlines

Clarus Therapeutics (NASDAQ:CRXT) Price Target Cut to $3.00
Clarus Therapeutics Misses Q1 EPS by 21c
Clarus Therapeutics (CRXT) to Release Earnings on Monday
Clarus Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRXT
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
$13.96 million
Book Value
($1.23) per share

Profitability

Net Income
$-40.62 million
Pretax Margin
-311.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
23,438,000
Market Cap
$9.41 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/26/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Clarus Therapeutics (NASDAQ:CRXT) Frequently Asked Questions

Is Clarus Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clarus Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Clarus Therapeutics stock.
View analyst ratings for Clarus Therapeutics
or view top-rated stocks.

When is Clarus Therapeutics' next earnings date?

Clarus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Clarus Therapeutics
.

How were Clarus Therapeutics' earnings last quarter?

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) released its quarterly earnings data on Monday, May, 16th. The company reported ($0.61) earnings per share (EPS) for the quarter. The firm had revenue of $4.01 million for the quarter.
View Clarus Therapeutics' earnings history
.

What price target have analysts set for CRXT?

4 brokerages have issued 1 year price targets for Clarus Therapeutics' shares. Their forecasts range from $1.50 to $20.00. On average, they anticipate Clarus Therapeutics' stock price to reach $7.90 in the next year. This suggests a possible upside of 1,978.9% from the stock's current price.
View analysts' price targets for Clarus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Clarus Therapeutics' key executives?
Clarus Therapeutics' management team includes the following people:
  • Dr. Robert E. Dudley Ph.D., Founder, Pres, CEO & Director (Age 67, Pay $800.67k)
  • Mr. Richard Dale Peterson, Chief Financial Officer (Age 54, Pay $613.99k)
  • Mr. Frank A. Jaeger M.A., M.B.A., Chief Commercial Officer (Age 51, Pay $510.3k)
  • Mr. Steve Stark, VP of Commercial Analytics & Operations
  • Mr. Steven A. Bourne CPA, Chief Admin. Officer (Age 60)
  • Ms. Kara J. Stancell, VP of Investor Relations & Corp. Communications
  • Ms. Rozita Passarella, VP of Marketing
  • Mr. Mike Cleveland, VP of Sales
  • Dr. Jay Newmark M.B.A., M.D., Chief Medical Officer
  • Mr. James Holloway, Sr. VP of Manufacturing & Supply
What is Clarus Therapeutics' stock symbol?

Clarus Therapeutics trades on the NASDAQ under the ticker symbol "CRXT."

Who are Clarus Therapeutics' major shareholders?

Clarus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.14%).

Which major investors are buying Clarus Therapeutics stock?

CRXT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Clarus Therapeutics?

Shares of CRXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clarus Therapeutics' stock price today?

One share of CRXT stock can currently be purchased for approximately $0.38.

How much money does Clarus Therapeutics make?

Clarus Therapeutics has a market capitalization of $9.41 million and generates $13.96 million in revenue each year.

How many employees does Clarus Therapeutics have?

Clarus Therapeutics employs 2 workers across the globe.

What is Clarus Therapeutics' official website?

The official website for Clarus Therapeutics is www.clarustherapeutics.com.

How can I contact Clarus Therapeutics?

Clarus Therapeutics' mailing address is 15 E. PUTNAM AVENUE SUITE 363, GREENWICH CT, 06830. The company can be reached via phone at 847-562-4300.

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.